Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer

[1]  Jean-Claude Laprie,et al.  Trend Analysis , 1996, The SAGE Encyclopedia of Research Design.

[2]  Yuyan Zhu,et al.  TRIB3 Promotes the Malignant Progression of Bladder Cancer: An Integrated Analysis of Bioinformatics and in vitro Experiments , 2021, Frontiers in Genetics.

[3]  E. Cuppen,et al.  Molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma , 2021, bioRxiv.

[4]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[5]  Jose Espejo Valle-Inclan,et al.  GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing , 2021, Genome Biology.

[6]  S. Monti,et al.  How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression , 2020, International journal of molecular sciences.

[7]  Daniel L. Cameron,et al.  Unscrambling cancer genomes via integrated analysis of structural variation and copy number , 2020, bioRxiv.

[8]  A. Lenis,et al.  Bladder Cancer: A Review. , 2020, JAMA.

[9]  Andrew Menzies,et al.  Extensive heterogeneity in somatic mutation and selection in the human bladder , 2020, Science.

[10]  F. Radvanyi,et al.  Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer , 2020, Genome Medicine.

[11]  Assessment of Luminal and Basal Phenotypes in Bladder Cancer , 2020, Scientific Reports.

[12]  R. Huddart,et al.  ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001. , 2020 .

[13]  A. McCluskey,et al.  The aryl hydrocarbon receptor (AhR) as a breast cancer drug target , 2019, Medicinal research reviews.

[14]  Ashley M. Laughney,et al.  Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity , 2019, Nature Communications.

[15]  A. Atala.  Re: Mouse and Human Urothelial Cancer Organoids: A Tool for Bladder Cancer Research. , 2019, The Journal of urology.

[16]  Z. Mo,et al.  Single-Cell Transcriptomic Map of the Human and Mouse Bladders. , 2019, Journal of the American Society of Nephrology : JASN.

[17]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[18]  A. Hanberg,et al.  Histopathological features of the proper gastric glands in FVB/N-background mice carrying constitutively-active aryl-hydrocarbon receptor , 2019, BMC Gastroenterology.

[19]  Harry Begthel,et al.  Mouse and human urothelial cancer organoids: A tool for bladder cancer research , 2019, Proceedings of the National Academy of Sciences.

[20]  S. Szymańska,et al.  On histOpathOlOgical features , 2019 .

[21]  A. Vlahou,et al.  Proteome‐based classification of Nonmuscle Invasive Bladder Cancer , 2019, International journal of cancer.

[22]  S. Sleijfer,et al.  Pan-cancer whole-genome analyses of metastatic solid tumours , 2018, bioRxiv.

[23]  Vinicius S. Chagas,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2018, Cell.

[24]  X. Coumoul,et al.  AhR signaling pathways and regulatory functions , 2018, Biochimie open.

[25]  S. Saxena,et al.  Overexpression of COX2 indicates poor survival in urothelial bladder cancer. , 2018, Annals of diagnostic pathology.

[26]  Joseph G Ibrahim,et al.  Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences , 2018, bioRxiv.

[27]  Chris Berdik.  Unlocking bladder cancer , 2017, Nature.

[28]  Icgc,et al.  Pan-cancer analysis of whole genomes , 2017, bioRxiv.

[29]  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target , 2017, Archives of Toxicology.

[30]  Yitong Li,et al.  Structural hierarchy controlling dimerization and target DNA recognition in the AHR transcriptional complex , 2017, Proceedings of the National Academy of Sciences.

[31]  Mauro J. Muraro,et al.  A Single-Cell Transcriptome Atlas of the Human Pancreas , 2016, Cell systems.

[32]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[33]  C. Mendelsohn,et al.  Formation and regeneration of the urothelium , 2014, Current opinion in organ transplantation.

[34]  The Cancer Genome Atlas Research Network.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[35]  R. Montironi,et al.  HtrA1 in human urothelial bladder cancer: A secreted protein and a potential novel biomarker , 2013, International journal of cancer.

[36]  Miriam K. Konkel,et al.  A Comparison of 100 Human Genes Using an Alu Element-Based Instability Model , 2013, PloS one.

[37]  F. Montorsi,et al.  Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. , 2013, Cancer epidemiology.

[38]  C. Elferink,et al.  The Tumor Suppressor Kruppel-Like Factor 6 Is a Novel Aryl Hydrocarbon Receptor DNA Binding Partner , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[39]  John L. Gore,et al.  The costs of non-muscle invasive bladder cancer. , 2013, The Urologic clinics of North America.

[40]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[41]  Q. Cui,et al.  Identification of the Ah-receptor structural determinants for ligand preferences. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[43]  J. Raufman,et al.  Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[44]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[45]  Bin Zhao,et al.  Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  Dalei Wu,et al.  Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression. , 2011, Archives of biochemistry and biophysics.

[47]  Matko Bosnjak,et al.  REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.

[48]  S. Eltom,et al.  Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor. , 2011, Current cancer drug targets.

[49]  Bin Zhao,et al.  CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[50]  B. Kaina,et al.  The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. , 2010, Carcinogenesis.

[51]  H. Kakizaki,et al.  Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer. , 2010, The Journal of urology.

[52]  Cancer Facts & Figures 2021 , 2010 .

[53]  Ruben Abagyan,et al.  Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands. , 2009, Journal of medicinal chemistry.

[54]  L. Sheffield.  Malignant Transformation of Mammary Epithelial Cells Increases Expression of Leptin and Leptin Receptor , 2008, Endocrine research.

[55]  L. Klotz,et al.  Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation , 2007, Proceedings of the National Academy of Sciences.

[56]  Alessandro Pandini,et al.  Structural and functional characterization of the aryl hydrocarbon receptor ligand binding domain by homology modeling and mutational analysis. , 2007, Biochemistry.

[57]  Sun-Hee Kim,et al.  Novel Compound 2-Methyl-2H-pyrazole-3-carboxylic Acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) Prevents 2,3,7,8-TCDD-Induced Toxicity by Antagonizing the Aryl Hydrocarbon Receptor , 2006, Molecular Pharmacology.

[58]  G. Sauter,et al.  High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. , 2005, International journal of oncology.

[59]  Joshua J. Neumiller,et al.  Activation of the aryl hydrocarbon receptor increases pulmonary neutrophilia and diminishes host resistance to influenza A virus. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[60]  M. Denison,et al.  Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. , 2003, Annual review of pharmacology and toxicology.

[61]  A. Hanberg,et al.  A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Jurka,et al.  Inverted Alu repeats unstable in yeast are excluded from the human genome , 2000, The EMBO journal.

[63]  Y. Fujii‐Kuriyama,et al.  Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[65]  J. P. Whitlock,et al.  DNA Binding by the Heterodimeric Ah Receptor , 1996, The Journal of Biological Chemistry.

[66]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[67]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.